As the Northern Hemisphere welcomes Spring 2023 the new season of industry conferences and symposia kicks off. And after the return to face to face meetings last year and the positive experiences had there, Ten Bio is very enthusiastic about our planned presence at a number of important events this year.

Our schedule starts with our founders attending the PC Project Patient satellite meeting at the American Academy of Dermatology being held this year in the fabulous city of New Orleans from 17th to 21st March. Pachyonychia Congenita Project (PC Project) is a charity organisation which connects patients, researchers, physicians and industry partners in a united and global effort to help those who suffer from the debilitating effects of this rare, genetic skin disease. Our founders are proud to have worked closely with PC Project for several years and are looking forward to continuing supporting the charity’s efforts.

Our abbreviated stay at AAD allows the Ten Bio team to be at the 62nd Society of Toxicology (SOT) in Nashville between 19th and 23rd March. We attended and exhibited at SOT last year in San Diego. Our analysis of the event and the quality of contacts made has made the decision to attend again very simple. Our team looks forward to sharing our latest offerings based around our TenSkin™ model, augmenting existing relationships and making new ones in Nashville.

Post SOT the Ten Bio exhibition booth will decamp first to Edinburgh in Scotland and then to Washington DC for first the Skin Vaccination Summit organised by MEDICANmm at the Royal College of Physicians of Edinburgh in late March and then to the World Vaccine Congress back in the US. Our co-founder Dr Michael Conneely will be presenting on the advantages to evaluating skin biological responses in the TenSkin™ platform to the Skin Vaccination Summit audience on Thursday 30th March. The focus at this latter event is on ‘R&D + Strategic Partnering for The Global Vaccine Industry’ and it runs from 3rd to 6th April. Ten Bio is attending and exhibiting at both of these vaccine based congress to gain intelligence about vaccine administration and testing, and to raise awareness of Ten Bio’s ex vivo test platform TenSkin™ in vaccine R&D. At Ten Bio we have been collaborating with academia to explore the merits of TenSkin™ in the use of micro-needles and needleless administrations. The attributes of TenSkin™ again provide the best model by which to predict the physiological and anatomical reactions of the recipients to vaccine injections. This is another example of Ten Bio’s commitment to the 3 Rs of medical testing – Replace, Reduce, Refine.

In May this year Ten Bio will take its messages further afield – to the global session of the International Societies for Investigative Dermatology (ISID) to be held at the Keio Plaza Hotel, Tokyo between 10th and 13th of the month. This is a very exciting new geography for Ten Bio. Ten Bio will be hosting a booth to engage with the diverse set of delegates attending the meeting and is also to present on how mechanical tension influences the immuno-competency of ex vivo human skin tissue.

In addition, and to make best use of our time in Japan, around the conference schedule the management will be visiting a number of local companies active in dermatology testing in the fields of aesthetic dermatology, wound management and new pharmaceutical testing. Our efforts to engage with the industry in Japan have been well supported by the excellent efforts of Scottish Development International Ltd., an agency of the Scottish government that is active in supporting the international ambitions of Scotland’s industries. Ten Bio has benefited as a result of the actions by the SDI staff in Scotland and its team of international representatives. Ten Bio wants to use this opportunity to thank SDI central and its people in Japan for their guidance, ongoing support and introductions.

Ten Bio’s schedule of events in Spring 2023 is already busy but we remain attentive to other opportunities where we can share the Ten Bio story. We look forward to attending events that enable our team to engage with the presenters, other contributors, delegates and exhibitors to hear more of their outstanding needs and to investigate how Ten Bio can address those needs. We look to take the field of dermatology testing further away from reliance on animal models and into a new era of enhanced ex vivo testing.

We look forward to those future in person interactions and to hearing from all parties through our website and LinkedIn channels.

Ken Fyvie

March 2023